A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy

British Journal of Ophthalmology

Volumn 96, Issue 4, 2012, Pages 587-590

  Van Geest, Rob J ^a   Lesnik Oberstein, Sarit Y ^a   Tan, H Stevie ^a   Mura, Marco ^a   Goldschmeding, Roel ^b   Van Noorden, Cornelis J F ^a   Klaassen, Ingeborg ^a   Schlingemann, Reinier O ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CONNECTIVE TISSUE GROWTH FACTOR; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; OCULAR FIBROSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VITRECTOMY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONNECTIVE TISSUE GROWTH FACTOR; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84858332402     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-301005     Document Type: Article

References (26)

1. Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540-53. (Pubitemid 39281419)
2. Kuiper EJ, van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008;3:e2675.
3. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
4. Leask A, Parapuram SK, Shi-Wen X, et al. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 2009;3:89-94.
5. He S, Jin ML, Worpel V, et al. A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization. Arch Ophthalmol 2003;121:1283-8. (Pubitemid 37128406)
6. Kuiper EJ, Hughes JM, Van Geest RJ, et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci 2007;48:4267-76. (Pubitemid 351261058)
7. Suzuma K, Naruse K, Suzuma I, et al. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 2000;275:40725-31. (Pubitemid 32054890)
8. Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002;16:219-21.
9. Jang HS, Kim HJ, Kim JM, et al. A novel ex vivo angiogenesis assay based on electroporation-mediated delivery of naked plasmid DNA to skeletal muscle. Mol Ther 2004;9:464-74.
10. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 2005;32:S43-7. (Pubitemid 43080915)
11. Martin DF, Maguire MG, Ying GS, et al CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
12. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86.
13. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50.
14. Avery RL, Pearlman J, Peramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-715.
15. di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:785-91.
16. Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009;116:1943-8.
17. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011;5:CD008214.
18. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700. (Pubitemid 44620378)
19. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-16. (Pubitemid 351224097)
20. El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 2011;118:636-41.
21. Kuiper EJ, de Smet MD, van Meurs JC, et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 2006;124:1457-62. (Pubitemid 44537147)
22. Batman C, Ozdamar Y. The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 2010;41:190-5.
23. Hwang JC, Del Priore LV, Freund KB, et al. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2011;42:6-11.
24. Wu L, Arvalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-19. (Pubitemid 351643150)
25. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7. (Pubitemid 350167096)
26. Leask A. Trial by CCN2: a standardized test for fibroproliferative disease? J Cell Commun Signal 2009;3:87-8.